Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 1/20 | 0.50 |
| ▸ | CCNK | O75909 | 10/20 | 0.48 |
| ▸ | CDK12 | Q9NYV4 | 10/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.48 |
| ▸ | CDK2 | P24941 | 8/20 | 0.48 |
| ▸ | CDK7 | P50613 | 8/20 | 0.48 |
| ▸ | CCNH | P51946 | 8/20 | 0.48 |
| ▸ | MNAT1 | P51948 | 6/20 | 0.48 |
| ▸ | AURKA | O14965 | 6/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.47 |
| ▸ | PLK4 | O00444 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.45 |
| ▸ | PIK3C2G | O75747 | 6/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.44 |
| ▸ | CDK9 | P50750 | 3/20 | 0.44 |
| ▸ | CDK13 | Q14004 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469527 | 0.88 | CCNK (0.46) | CCNKCDK12CCNA2CDK2CDK7 | |
| SCHEMBL17469559 | 0.85 | AURKA (0.45) | AURKAAURKBPLK4BRD4LRRK2 | |
| SCHEMBL17469565 | 0.81 | EGFR (0.43) | AURKAAURKBPLK4BRD4LRRK2 | |
| SCHEMBL16065777 | 0.80 | DCLK1 (0.59) | MAPK7CDK7CCNHAURKAAURKB | |
| SCHEMBL16065773 | 0.80 | ITK (0.59) | MAPK7CCNKCDK12CCNA2CDK2 | |
| SCHEMBL22663723 | 0.76 | TNK2 (0.43) | MAPK7 | |
| SCHEMBL20682528 | 0.75 | DCLK1 (0.43) | MAPK7CCNKCDK12CCNA2CDK2 | |
| SCHEMBL17465845 | 0.70 | EGFR (0.57) | AURKAAURKBPLK4BRD4LRRK2 | |
| SCHEMBL16065805 | 0.67 | MAPK7 (1.00) | MAPK7AURKAAURKBBRD4LRRK2 | |
| SCHEMBL16655035 | 0.66 | CCNK (0.67) | CCNKCDK12CCNA2CDK2CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3738964-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9676792-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | MAPK7 292/4885CCNK 289/4885CDK12 318/4885 |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | MAPK7 292/4885CCNK 289/4885CDK12 318/4885 |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | MAPK7 292/4885CCNK 289/4885CDK12 318/4885 |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | MAPK7 292/4885CCNK 289/4885CDK12 318/4885 |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | MAPK7 292/4885CCNK 289/4885CDK12 318/4885 |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | MAPK7 292/4885CCNK 289/4885CDK12 318/4885 |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | MAPK7 292/4885CCNK 289/4885CDK12 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.